Anagenex, a pioneering drug discovery company pairing large-scale data generation with machine learning to discover the next generation of small molecule medicines, has closed a $30 million Series A financing round led by Catalio Capital Management, with participation from existing investors Lux Capital, Khosla Ventures, Obvious Ventures, Air Street Capital, and Menlo Ventures.

Anagenex is a pre-clinical biotechnology innovator advancing drug discovery through its small molecule directed evolution platform. The company's unique, machine learning-driven technology enables Anagenex to discover first-in-class and best-in-class small molecule medicines addressing historically intractable targets. With a team of highly experienced scientists and engineers, the company has offices in the San Francisco Bay area and Woburn, Mass.